TrialsgrambetaRCTs are beautiful

NAVIGATOR

2021

Tezepelumab in Severe, Uncontrolled Asthma

In 1,061 patients with severe uncontrolled asthma, tezepelumab 210 mg SC every 4 weeks reduced the annualised asthma exacerbation rate compared with placebo.

Result

Efficacy: Annualised asthma exacerbation rateRR 0.44 (95% CI 0.37-0.53)

Below 1 favours tezepelumab 210 mg SC every 4 weeks, above 1 favours placebo.

Event rates Tezepelumab 210 mg SC every 4 weeks 0.93 vs placebo 2.10 exacerbations/year

Also reported: Benefit preserved in eosinophils <300/µL (RR 0.59).

Original publication
Subtopic
Anti-TSLP biologic
Design
Multicentre phase-3 RCT
Relevance
Important: one of several pillars.
Source
Menzies-Gow A, et al. N Engl J Med. 2021;384(19):1800-1809.doi 10.1056/NEJMoa2034975

Discussion & critique

First biologic effective across all asthma phenotypes, including low-eosinophil disease; FDA-approved 2021.